Our
Mission
Transform how the immune system targets and fights disease to create a new generation of targeted cancer treatments and infectious disease vaccines.
LEARN MOREPowerful
Platforms
Our Versamune® T cell activating platform trains the immune system to unleash a powerful targeted T cell attack and could dramatically improve treatment and outcomes for patients with cancer.
Our combination PDS01ADC and Versamune® platform unleashes a powerful targeted T cell attack on cancer while targeting the tumor’s internal environment to suppress and breakdown the tumors defenses against T cells.
About Us
PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body’s own immune system to induce a powerful T cell response, most have been unsuccessful in overcoming the tumor’s ability to protect itself against the immune system and also inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack.
Our proprietary targeted technologies are designed to deliver IL-12 into the tumor’s inner environment to suppress the tumor’s ability to protect against T cells while simultaneously generating a potent targeted T cell attack on the cancer.
Versamune® Mechanism of Action Video